Cardiac Rehabilitation of Children and Adolescent With Long QT Syndrome (RYTHMO'FIT)

July 28, 2025 updated by: University Hospital, Montpellier

Children and adolescents with inherited cardiac arrhythmia su ch Long QT Syndrome (LQTS) have lower physical and quality of life than their healthy peers. A multi-component cardiac rehabilitation, including an exercise training program and education program, might counteract those effects.

The goal of this pilot study is to evaluate the security, feasibility, and benefits of a cardiac rehabilitation program in children with LQTS aged between 6 to 18 years old.

The main question[s] it aims to answer are:

  • Is center-based cardiac rehabilitation safe and feasible for children with LQTS?
  • Does a 12-week cardiac rehabilitation program improve physical fitness and quality of life?

Study Overview

Detailed Description

Physical fitness is an independent predictor of all-cause mortality and global health in the general population. Assessments of cardiorespiratory and muscle fitness in children with chronic illness are growing in interest, even in less prevalent chronic diseases. For instance, children and adolescents with Long QT Syndrome (LQTS) have lower cardiorespiratory fitness, muscle strength, and quality of life than their healthy peers.

A multi-component cardiac rehabilitation including an exercise training program and education program might counteract this lowered physical fitness.

The RYTHMO'FIT pilot study seeks to test the security, and feasibility, and to evaluate the benefits of an innovative center-based program to improve physical and mental health in children and adolescents with LQTS.

In this retrospective study, eight children had undergone a 12-week program, within each session composed by:

  • A 1-hour exercise training session with a trained exercise physiologist: resistance training, aerobic training, stretching, and different activity (e.g., basketball, handball, football, hockey)
  • A 30-min educational workshop with a specialist nurse (e.g., beta-blockade, sports participation, healthy behaviors).
  • A 10-min medical interview with a cardiologist to have feedback from parents and patients on each session and the past 7 seven days.

We hypothesized the RYTHMO'FIT study is safe, feasible, and provides benefits for mental and physical health in children and adolescents with LQTS. If the results of this pilot study are positive, they will lead to a larger randomized multicentric controlled trial to evaluate the effectiveness of a hybrid cardiac rehabilitation program in children, adolescents, and young adults with LQTS.

Study Type

Observational

Enrollment (Actual)

8

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Montpellier, France, 34295
        • University Hospital of Montpellier - Arnaud de Villeneuve Hospita
      • Palavas-les-Flots, France, 34250
        • Saint-Pierre Institute

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Children aged 8 to 18 years with an LQTS.

Description

  • Children and adolescents, aged 6 to 18 years old, diagnosed with congenital LQTS and had been recently under medical check-up in our last study QUALIMYORYTHM
  • With impaired cardiorespiratory fitness (VO2 peak <80% of predicted values or VAT <55% of predicted values) or with normal cardiorespiratory fitness but requiring patient education and information on limits/security in taking part in sports participation.
  • Willingness and ability for parents and children to take part in a 12-week center-based program (e.g., availability during the school period, transportation options)
  • Informed consent of parents or legal guardians, and oral assent of children.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Security
Time Frame: At week 12
Count and specify any cardiac events on the ECG scope during each session. Reporting of related and non-related event during the past 7 days through short questionnaire each week.
At week 12
Recruitment rates
Time Frame: At week 12
Number of participants who completed baseline assessment compared to the number who were eligible (expressed in %).
At week 12
Retention rates
Time Frame: At week 12
Participants who participated in the 12-week intervention and completed the follow-up assessments at the end of the program (expressed in %).
At week 12
Adherence
Time Frame: At week 12
Percentage exercise sessions attained by participants compared to number of sessions proposed.
At week 12

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change on cardiorespiratory fitness
Time Frame: between week 0 and week 12
Assessing the following variables by cardiopulmonary exercise testing: peak oxygen uptake (VO2peak), ventilatory anaerobic threshold (VAT), ventilatory efficiency (VE/VCO2 slope), maximum heart rate (HR), oxygen pulse (VO2/HR), maximal power, respiratory exchange ratio.
between week 0 and week 12
Change on muscle architecture
Time Frame: between week 0 and week 12
Assessing the following variables by ultrasounding: Anatomical cross sectional area, pennation angle, fascicle length and muscle thickness
between week 0 and week 12
Change on muscle strength
Time Frame: between week 0 and week 12
Lower and upper limb maximal isometric strength by knee extension and handgrip test, respectively. Lower body explosive muscular strength was assessed by standing long broad jump.
between week 0 and week 12
Change on physical activity level
Time Frame: between week 0 and week 12
Time spent in vigorous, moderate-to-vigorous, light physical activity assessed by waist-worn tri axial accelerometer during 7 days.
between week 0 and week 12
Change on Self reported total score of the Pediatric Quality of Life Inventory (PedsQL) 4.0 questionnaire
Time Frame: between week 0 and week 12
between week 0 and week 12
Change on Proxy-reported total score of the Pediatric Quality of Life Inventory (PedsQL)
Time Frame: between week 0 and week 12
between week 0 and week 12
Pediatric Quality of Life Inventory (PedsQL) 4.0 Health-related quality (HRQoL ) of life questionnaire score per dimension (self and proxy reports)
Time Frame: between week 0 and week 12
between week 0 and week 12
Change on cardiological outcomes
Time Frame: between week 0 and week 12
Electrocardiographic at rest (QTc, heart rate, PR, QRS interval time) and echocardiography (LVEF, IVSd, IVSs, LVEDV, E/A ratio)
between week 0 and week 12

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Pascal AMEDRO, Professor, University Hospital of Bordeaux - Haut-Levêque Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 2, 2022

Primary Completion (Actual)

March 7, 2023

Study Completion (Actual)

December 31, 2024

Study Registration Dates

First Submitted

July 4, 2023

First Submitted That Met QC Criteria

July 19, 2023

First Posted (Actual)

July 27, 2023

Study Record Updates

Last Update Posted (Actual)

July 31, 2025

Last Update Submitted That Met QC Criteria

July 28, 2025

Last Verified

July 1, 2025

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pediatric ALL

Subscribe